다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

INCY

Incyte (INCY)

Incyte Corporation

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:INCY

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/04/30	20:00	Business Wire	Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs	NASDAQ:INCY	Incyte Corporation
2024/04/24	07:11	Business Wire	Incyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorie	NASDAQ:INCY	Incyte Corporation
2024/04/24	07:01	Business Wire	Incyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekannt	NASDAQ:INCY	Incyte Corporation
2024/04/23	20:00	Business Wire	Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists	NASDAQ:INCY	Incyte Corporation
2024/04/11	21:00	Business Wire	Incyte to Report First Quarter Financial Results	NASDAQ:INCY	Incyte Corporation
2024/04/01	21:30	Business Wire	Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	NASDAQ:INCY	Incyte Corporation
2024/03/30	05:30	Business Wire	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:INCY	Incyte Corporation
2024/03/11	21:57	Business Wire	Incyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekannt	NASDAQ:INCY	Incyte Corporation
2024/03/11	21:57	Business Wire	Incyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modérée	NASDAQ:INCY	Incyte Corporation
2024/03/11	19:06	Business Wire	Incyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaire	NASDAQ:INCY	Incyte Corporation
2024/03/11	18:53	Business Wire	Incyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vor	NASDAQ:INCY	Incyte Corporation
2024/03/11	05:05	Business Wire	Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis	NASDAQ:INCY	Incyte Corporation
2024/03/11	05:05	Business Wire	Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa	NASDAQ:INCY	Incyte Corporation
2024/03/05	04:38	Business Wire	De nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)	NASDAQ:INCY	Incyte Corporation
2024/03/05	04:02	Business Wire	Neue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiert	NASDAQ:INCY	Incyte Corporation
2024/03/04	22:00	Business Wire	New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting	NASDAQ:INCY	Incyte Corporation
2024/03/01	00:19	Business Wire	Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI	NASDAQ:INCY	Incyte Corporation
2024/02/29	21:30	GlobeNewswire Inc.	Knight Therapeutics Announces Launch of Minjuvi® in Brazil	NASDAQ:INCY	Incyte Corporation
2024/02/28	23:11	Business Wire	Incyte annonce que la Food and Drug Administration des États-Unis accorde une évaluation prioritaire à l’axatilimab pour le traitement de la maladie chronique du greffon contre l’hôte	NASDAQ:INCY	Incyte Corporation
2024/02/28	21:15	Business Wire	Incyte gibt bekannt, dass die US-Arzneimittelbehörde FDA Axatilimab für die Behandlung der chronischen Graft-Versus- Host-Krankheit als vorrangig eingestuft hat	NASDAQ:INCY	Incyte Corporation
2024/02/28	06:08	Business Wire	Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease	NASDAQ:INCY	Incyte Corporation
2024/02/17	06:04	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:INCY	Incyte Corporation
2024/02/17	02:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/17	02:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/17	02:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/17	02:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/17	02:48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/17	02:47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/02/15	22:00	Business Wire	Incyte to Present at Upcoming Investor Conference	NASDAQ:INCY	Incyte Corporation
2024/02/15	02:33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation

검색 관련기사 보기:NASDAQ:INCY

1 2 3 4 5 6 7 8 9 10 다음 >>

US Dollar vs Euro

Financial Select Sector

Verizon Communications

American Express

Gold vs US Dollar

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관